MARS Bioimaging

MARS Bioimaging Limited specializes in advanced imaging technologies, focusing on the commercialization of spectral photon-counting computed tomography (CT) systems for enhanced diagnostic capabilities in medical and research settings. MARS Bioimaging Limited is dedicated to innovating imaging solutions through spectral photon-counting computed tomography systems. The company is based in Christchurch, New Zealand. Founded in 2007 by Phil Butler and Prof Anthony Butler, MARS Bioimaging was established to improve diagnostic imaging technologies for medical applications. The founder has a rich history in imaging technology, having previously developed advanced detection systems for various applications. MARS Bioimaging Ltd specializes in advanced imaging technologies, particularly in the development and commercialization of spectral photon-counting computed tomography (CT) systems. Their flagship product, the MARS Microlab 5X120, leverages cutting-edge Medipix3RX detector technology, enabling high-resolution color CT imaging for preclinical research applications. This system is designed for a variety of end users, including researchers in academic institutions and clinicians seeking improved diagnostic tools for conditions such as atherosclerosis and cancer. The MARS system allows for non-invasive imaging that enhances the ability to conduct comprehensive analyses of biological tissues, thus supporting applications in developing novel contrast agents and evaluating tissue biochemistry. MARS Bioimaging's products primarily cater to markets in North America, Europe, and Asia, with a specific focus on countries such as the United States, Germany, and Japan, where demand for advanced medical imaging technology is robust. MARS Bioimaging generates revenue through the sale of its specialized imaging systems, partnerships with research institutions, and collaborations with medical professionals. The company engages in direct transactions with clients, primarily B2B, supplying its advanced imaging technology to hospitals, clinics, and research laboratories. These transactions often involve upfront payments for the equipment, followed by ongoing service agreements for software updates and technical support. As clients integrate MARS imaging technology into their workflows, the firm may also offer subscription-based access to advanced analysis tools, enhancing diagnostic accuracy and research capabilities. The pricing structure for these products reflects the technology's critical role in preclinical and clinical imaging applications.

1. Series A

   Jan 14, 2026

   Amount

   $7.4M

   Investors

   Locked